Tag: DRRX

Blue Horseshoe Stocks: Reviewing Friday’s Picks & More

Recapping Friday’s Options Ideas

We made it a point to pass along a handful of quick-strike options ideas on Friday. We mentioned the high-risk, high-reward nature of trading weekly contracts on a Friday, and we certainly were rewarded as every single idea we formulated bore fruit, to varying degrees.

Here’s a breakdown of the prime possibilities for profit that we observed:

Netflix, Inc. NFLX – The rather broad range we provided for NFLX were Weekly $595-612.50 Calls, and every set of contracts in that range made highly impressive moves:

$595 Calls – Daily Range: 6.58-23.00 – Max Gain: 250%
$597.50 Calls – Daily Range: 5.30-20.67 – Max Gain: 290%
$600 Calls – Daily Range: 3.63-18.02 – Max Gain: 396%
$602.50 Calls – Daily Range: 2.80-15.45 – Max Gain: 452%
$605 Calls – Daily Range: 1.10-12.82 – Max Gain: 1065%
$607.50 Calls – Daily Range: 1.00-10.62  – Max Gain: 962%
$610 Calls – Daily Range: .80-8.17 – Max Gain: 921%
$612.50 Calls – Daily Range: .53-5.54 – Max Gain: 945%

____

Apple, Inc. AAPL – Our idea for AAPL was the Weekly $128 and $129 Calls, and a relatively volatile outing brought several significant swing-trade opportunities in each:

$128 Calls started out by first trading from an early low of 1.06 to 1.58 (+49%). It then pulled back to find support at .53 before taking off again to hit .99 (+86%). That swing was followed another ranging from .43-.92 (114%), and then by a final dip to .53 and run back to .81 (+53).

$129 Calls traded with similar action; four distinct swings of  53%, 134%, 167% and 300% occurred during the session.
____

Petroleo Brasiliero S.A. (Petrobras) PBR – The PBR Weekly $10 Calls that we tagged for observation made a monster move from .03-.20, yielding the chance at gains of up to 566%

The stock is gapping up in the premarket today, so we’re going to continue keep our eyes on PBR. Our interest to start out the week will be in the Weekly $10 and 10.50 Calls for potential daytrade swing-trade opportunities.

____

Huge congratulations go out to any of our followers that were able to bank some hefty gains off of Friday’s excellent options ideas!

Pazoo, Inc. PZOO

We’re touching base with PZOO this morning to update our readers on what the stock has been up to lately. Many of you will recall the monumental April this stock had; we initiated coverage on April 1st, and PZOO essentially spent the entire month on an uptrend. The total range we observed over the course of the month went from .0049 to .0204, which amounted to an epic 316% swing.

We put the stock on the back burner this month as it consolidated off of those impressive highs, and we want to rehash our interest in this play now that it appears to be headed toward its next leg-up. We’d also suggest that folks check out the PR released by the company on Friday, which alludes to its partner’s ribbon-cutting on the Nevada medical marijuana testing facility that we’ve been anticipating.

We’ve prepared a video outlining the key aspects of the PZOO Chart:
CLICK TO VIEW VIDEO CHART

MagneGas Corp. MNGA

We also want to pat ourselves on the back for a timely call of MNGA on Friday. We caught the news release highlighting the company’s contract with the US Navy, and it was enough to send the stock on a respectable intraday rip.

MNGA traded in a daily range from 1.08-1.48, which represented a healthy increase of 37% The move occurred on over 17X the 3-month average trading volume, and the stock closed just under the high of day, so we’ll be interested to see how the action unfolds as we kick off a new trading week today.

Extended Watchlist:
SGYP, PTBI, PSTI, DRRX, OSUR, ANN

Blue Horseshoe Stocks: NVAX, NQ & More

Novavax, Inc. NVAX 

NVAX is the latest Ebola-related stock to catch our eye, and while the initial fear that was driving a lot of these plays has calmed as people realize that the virus doesn’t exactly spread like wildfire, there is much being made of efforts to find a working vaccine and NVAX is attempting to answer that call.

The company announced today that it had presented at the 8th Vaccine and ISV Conference in Philadelphia on Sunday on what was called the first Ebola Vaccine Candidate based on the 2014 Guinea strain that caused the current outbreak in West Africa.

The company said it expects to begin Phase I testing by December, so we’re going to add NVAX to our watchlists for the time being. Additionally, the stock is gapping up to the tune of 10% here in the premarket, and the chart appears to have the possibility of a Golden Cross in the making.

NQ Mobile, Inc. NQ

This is a play we’ve tracked continuously since late this spring. After witnessing a nice move back in July from the low $4-range to the mid-$7’s, the stock had been under general consolidation until it found and bounced off of support about 6 weeks ago. It has made a nice steady recovery from that point on, and is gaining more traction this morning as it gaps up in the premarket on the heels of a PR.

The mobile security has just company submitted the necessary back-filings to once again become fully compliant, and no anomalies or adverse findings were uncovered, which adds another dimension to this play.

We also like the space NQ operates in- with mobile devices permeating every aspect of the current culture, the need for mobile security services such as those provided by NQ only stands to grow in the future.

Side Note:
PTIE, DRRX (Two that are gapping down significantly; we will want to watch for an eventual bounce)

Extended Watchlist:
ISR, AEZS, TSEM, CEMI,

DRRX, PPHM & Extended Watchlist

Durect Corp. DRRX

We are putting DRRX on our radar this morning; it has recently come off of a bottom, and is gaining some momentum as it begins its recovery. Prior to May, this pharmaceutical play was trading at a base level well above 1.20, before seeing a large spike followed by a sharp dropoff. If DRRX can break through resistance at the 50DMA & 200DMA there’s a chance it could come up to fill that gap on the chart. A return to previous levels from here could yield gains of up to 20%

In addition to a connection with pharma giant Pfizer, the company has also gotten FDA acceptance of a New Drug Application (NDA) as outlined in yesterday’s PR:

CUPERTINO, Calif., June 20, 2013 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery. DURECT submitted the NDA as a 505(b)(2) application. The Prescription Drug User Fee Act (PDUFA) goal date (the date the FDA expects to complete its review of the NDA) has been confirmed as February 12, 2014.

Peregrine Pharmaceuticals, Inc. PPHM

Speaking of pharmaceutical plays, one of the stocks that we continuously monitor is PPHM. Many of you will remember back in May when the stock provided us with some serious opportunities for profit.

Recently PPHM has been in a marked downtrend, and as you can see on the chart below, indicators seem to confirm this fact. We are going to want to put this one on bottom watch over the next several sessions, as the resulting bounce/s could be significant.

Side Note: 

Since Ben Bernanke’s recent comments regarding the Fed’s upcoming tapering of quantitative easing measures, markets have been in freefall. If no reversal occurs and that remains the overall trend, we are going to want to keep an eye on SPY Puts, VIX/VXX Calls.

Extended Watchlist:
ONCI, ONCO, LIVE, KERX, MSTX  

Get Our FREE Daily Reports!

SUBSCRIBE